When citing an abstract from the 2018 annual meeting, please use the format below.

[Authors]. [Abstract Title]. Program No. XXX.XX. 2018 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2018. Online.

Basic-Translational-Clinical Roundtables

099. What We Know, What We Don't Know: How Can We Better Understand Alzheimer's Disease to Develop Effective Treatments?

Location: SDCC 10

Time: Sunday, November 4, 2018, 8:30 AM - 11:00 AM

Description: Alzheimer's disease (AD) is the most common cause of dementia. Genetics, environment, and lifestyle likely contribute to the development of AD. Recent genetic data suggest a key role for glia in influencing AD. AD pathology can now be detected by assessing biomarkers in living people, and many promising treatments are in development. This session will review an update of the main molecules that play a role in AD and discuss the current understanding of AD, new diagnostic methods, and treatments.

Organizer/Moderator: *D. M. HOLTZMAN
Dept Neurol., Washington Univ., SAINT LOUIS, MO

Disclosure: D.M. Holtzman: Washington University in St. Louis, Research grants from C2N Diagnostics, AbbVie, Eli Lilly, Denali, Co-founder and part owner of C2N Diagnostics, LLC, Scientific advisory board for C2N Diagnostics, Denali, Genentech, Proclara.

Speaker: R. Vassar
Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Disclosure: R. Vassar: F. Consulting Fees (e.g., advisory boards); Eisai, Inc..

Speaker: G. D. Rabinovici
UCSF, San Francisco, CA.

Disclosure: G.D. Rabinovici: B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; Avid Radiopharmaceuticals, Eli Lilly, Piramal, GE Healthcare. Other; Associate Editor, JAMA Neurology.

Speaker: P. S. Aisen
University of Southern California, San Diego, CA.

Disclosure: P.S. Aisen: B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; Lilly, Janssen. F. Consulting Fees (e.g., advisory boards); Merck, Biogen, Proclara, Roche, Kyowa Kirin, Verge, Samus, Novartis, ImmunoBrain Checkpoint.

Basic-Translational-Clinical Roundtables

263. Molecular Therapies for Neurological Diseases

Location: SDCC 10

Time: Monday, November 5, 2018, 8:30 AM - 11:00 AM

Description: This roundtable will highlight spinal muscular atrophy (SMA) as an example of the progress being made in translating knowledge of the molecular basis of a disease to therapies that transform how the disease is managed. Topics to be discussed include SMA background, antisense, gene therapy, and small molecule approaches to treat SMA. In addition, lessons learned from these development programs will be discussed, highlighting how they translate to other neurological diseases.

Organizer/Moderator: F. BENNETT
Ionis Pharmaceuticals, Carlsbad, CA

Disclosure: F. Bennett: Employee of Ionis Pharmaceuticals, Shareholder of Ionis Pharmaceuticals, Advisory Board for Experimental Therapeutic Center, Singapore.

Speaker: B. K. Kaspar
AveXis, a Novartis company, Chicago, IL.

Disclosure: B.K. Kaspar: A. Employment/Salary (full or part-time):; AveXis, a Novartis company. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Nationwide Children's Hospital, AveXis royalty and IP rights.

Speaker: O. Khwaja
F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND.

Disclosure: O. Khwaja: A. Employment/Salary (full or part-time):; Roche. F. Consulting Fees (e.g., advisory boards); Roche.

Speaker: J. Day;
Stanford, Stanford, CA.

Disclosure: None.

Basic-Translational-Clinical Roundtables

350. Rapid Antidepressant Action: Synaptic Mechanisms and Clinical Aspects

Location: SDCC 30E

Time: Monday, November 5, 2018, 1:30 PM - 4:00 PM

Description: The discovery of rapidly acting antidepressant treatments has generated tremendous enthusiasm. Ketamine, a glutamate receptor antagonist, produces rapid and sustained antidepressant responses in patients. Deep brain stimulation has also shown promise for the treatment of depression. The mechanisms underlying rapid antidepressant responses provide novel perspectives into mood disorders and their treatment. This panel will discuss these novel treatments and the mechanisms underlying their action.

Organizer/Moderator: E. T. KAVALALI
Dept. of Pharmacol., Vanderbilt Univ., Nashville, TN

Disclosure: E.T. Kavalali: None.

Speaker: R. Malinow
Neuroscience, UCSD, La Jolla, CA.

Disclosure: R. Malinow: None.

Speaker: H. S. Mayberg
Mount Sinai, New York, NY.

Disclosure: H.S. Mayberg: C. Other Research Support (receipt of drugs, supplies, equipment or other in-kind support); Medtronic, Abbott Labs: donation of research DBS devices. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Abbott Labs: IP licensing fees.

Speaker: J. H. Krystal
Yale School of Medicine, New Haven, CT.

Disclosure: J.H. Krystal: A. Employment/Salary (full or part-time):; Yale School of Medicine, VA Connecticut Healthcare System, Editor- Biological Psychiatry. B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant "Center for Translational Neuroscience of Alcoholism [CTNA-4], Pfizer Pharmaceuticals provides an investigational drug, PF-03463275, for research related to NIH grant "Translational Neuroscience Optimization of GlyT1 Inhibitor". E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); 1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995, 2) Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Applic, 3) Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States appl, 4): Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs "Methods for Treating Suicidal Ideation", Patent Application No. 14/197.767 filed on March 5, 2014, 5) Arias

A, Petrakis I, Krystal JH. – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Rese, 6): Chekroud, A., Gueorguieva, R., & Krystal, JH. "Treatment Selection for Major Depressive Disorder" [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission b, 7. Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on, Stock: ArRETT Neuroscience, Inc., Stock: Blackthorn Therapeutics, Inc., Stock: Biohaven Pharmaceuticals Medical Sciences, Stock: Spring Care, Inc., Stock Options: Biohaven Pharmaceuticals Medical Sciences. F. Consulting Fees (e.g., advisory boards); AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Heptares Therapeutics, Limited - (UK), Janssen Research & Development, L.E.K. Consulting, Otsuka America Pharmaceutical, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc, Takeda Industries, Taisho Pharmaceutical Co., Ltd, SAB: Bioasis Technologies, Inc., SAB: Biohaven Pharmaceuticals, SAB: Blackthorn Therapeutics, Inc., SAB: Broad Institute at MIT and Harvard, SAB: Lohocla Research Corporation, SAB:Pfizer Pharmaceuticals.

Basic-Translational-Clinical Roundtables

440. Neuroprosthetic Devices: A Patient's Perspective on Brain Computer Interfaces

Location: SDCC 10

Time: Tuesday, November 6, 2018, 8:30 AM - 11:00 AM

Description: Patients will talk about their physical limitations and why they participated in time-intensive research for scientific knowledge. They will cover the challenges, breakthroughs, and difficult decisions that come with wearing a neuroprosthetic device. They will also speak to the benefits, despite trial and error methodologies and invasive surgeries, of participating in brain-computer interface (BCI) research, how it has changed their lives, and where they believe researchers should push the future of BCI technologies.

Organizer/Moderator: *F. SOLZBACHER
Univ. of Utah, Salt Lake City, UT

Disclosure: F. Solzbacher: Blackrock Microsystems, Sentiomed, Blackrock Neuromed, Blackrock Microsystems, Fraunhofer.

Speaker: I. Burkhart
Quadriplegic Patient, University of Ohio, Columbus, OH.

Disclosure: I. Burkhart: None.

Speaker: K. Walgamott
Department of Bioengineering, University of Utah, Salt Lake City, UT.

Disclosure: K. Walgamott: None.

Speaker: N. Copeland
University of Pittsburgh, AL.

Disclosure: N. Copeland: None.

Speaker: N. Smith
California Institute of Technology, Pasadena, CA.

Disclosure: N. Smith: None.